Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial door Andrew R. Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T. Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E. Coupland, Geetha Menon, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Renata Walewska, Scott Marshall, Christopher P. Fox, Peter Hillmen

Volledige tekst